2017-08-10
Hitting the target in IDH2 mutant AML
Publication
Publication
Blood , Volume 130 - Issue 6 p. 693- 694
In this issue of Blood, Stein et al1 demonstrate the feasibility and clinical efficacy of targeted inhibition of mutant isocitrate dehydrogenase 2 (IDH2) in patients with acute myeloid leukemia (AML). In a related paper, Amatangelo et al2 investigate mechanisms of response in samples derived from the same patients.
| Additional Metadata | |
|---|---|
| doi.org/10.1182/blood-2017-06-790394, hdl.handle.net/1765/101549 | |
| Blood | |
| Organisation | Erasmus MC: University Medical Center Rotterdam |
|
Wouters, B. (2017). Hitting the target in IDH2 mutant AML. Blood (Vol. 130, pp. 693–694). doi:10.1182/blood-2017-06-790394 |
|